136 related articles for article (PubMed ID: 11095580)
1. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?
Ward ES; Pollack GM; Brouwer KL
Drug Metab Dispos; 2000 Dec; 28(12):1433-9. PubMed ID: 11095580
[TBL] [Abstract][Full Text] [Related]
2. Probenecid-associated alterations in valproate glucuronide hepatobiliary disposition: mechanistic assessment using mathematical modeling.
Ward ES; Pollack GM; Brouwer KL
J Pharmacol Exp Ther; 2001 Apr; 297(1):141-7. PubMed ID: 11259538
[TBL] [Abstract][Full Text] [Related]
3. Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions.
Booth CL; Pollack GM; Brouwer KL
Hepatology; 1996 Apr; 23(4):771-80. PubMed ID: 8666331
[TBL] [Abstract][Full Text] [Related]
4. In vitro mechanisms of probenecid-associated alterations in acetaminophen glucuronide hepatic disposition.
Turner KC; Brouwer KL
Drug Metab Dispos; 1997 Sep; 25(9):1017-21. PubMed ID: 9311615
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep.
Wong H; Rurak DW; Kumar S; Kwan E; Abbott FS; Riggs KW
Drug Metab Dispos; 2001 May; 29(5):664-75. PubMed ID: 11302932
[TBL] [Abstract][Full Text] [Related]
6. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?
Yeleswaram S
Drug Metab Dispos; 2001 May; 29(5):777-8. PubMed ID: 11374361
[No Abstract] [Full Text] [Related]
7. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats.
Yamamura N; Imura K; Naganuma H; Nishimura K
Drug Metab Dispos; 1999 Jun; 27(6):724-30. PubMed ID: 10348803
[TBL] [Abstract][Full Text] [Related]
8. Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats.
Brouwer KL; Hall ES; Pollack GM
Biochem Pharmacol; 1993 Feb; 45(3):735-42. PubMed ID: 8442771
[TBL] [Abstract][Full Text] [Related]
9. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers.
Addison RS; Parker-Scott SL; Eadie MJ; Hooper WD; Dickinson RG
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):715-21. PubMed ID: 11214782
[TBL] [Abstract][Full Text] [Related]
10. Concentration-dependent disposition of glucuronide metabolite of valproate.
Yu HY; Shen YZ
J Pharm Pharmacol; 2002 May; 54(5):633-9. PubMed ID: 12005358
[TBL] [Abstract][Full Text] [Related]
11. Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis.
Golden PL; Brouwer KR; Pollack GM
Pharm Res; 1993 Dec; 10(12):1765-71. PubMed ID: 8302764
[TBL] [Abstract][Full Text] [Related]
12. Influence of chronic hepatic failure on disposition kinetics of valproate excretion through a phase II reaction in rats treated with carbon tetrachloride.
Khemawoot P; Maruyama C; Tsukada H; Noda H; Ishizaki J; Yokogawa K; Miyamoto K
Biopharm Drug Dispos; 2007 Sep; 28(6):331-8. PubMed ID: 17617793
[TBL] [Abstract][Full Text] [Related]
13. Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance.
Kumar S; Wong H; Yeung SA; Riggs KW; Abbott FS; Rurak DW
Drug Metab Dispos; 2000 Jul; 28(7):845-56. PubMed ID: 10859159
[TBL] [Abstract][Full Text] [Related]
14. Effect of naproxen co-administration on valproate disposition.
Addison RS; Parker-Scott SL; Hooper WD; Eadie MJ; Dickinson RG
Biopharm Drug Dispos; 2000 Sep; 21(6):235-42. PubMed ID: 11304722
[TBL] [Abstract][Full Text] [Related]
15. Nonstationary disposition of valproic acid during prolonged intravenous infusion: contributions of unbound clearance and protein binding.
Arens TL; Pollack GM
Biopharm Drug Dispos; 2001 Sep; 22(6):243-9. PubMed ID: 11754040
[TBL] [Abstract][Full Text] [Related]
16. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits.
Yokogawa K; Iwashita S; Kubota A; Sasaki Y; Ishizaki J; Kawahara M; Matsushita R; Kimura K; Ichimura F; Miyamoto K
Pharm Res; 2001 Sep; 18(9):1320-6. PubMed ID: 11683247
[TBL] [Abstract][Full Text] [Related]
17. Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat.
Pollack GM; Brouwer KL
J Pharmacokinet Biopharm; 1991 Apr; 19(2):189-225. PubMed ID: 2013839
[TBL] [Abstract][Full Text] [Related]
18. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
Blotnik S; Bergman F; Bialer M
Drug Metab Dispos; 1996 May; 24(5):560-4. PubMed ID: 8723737
[TBL] [Abstract][Full Text] [Related]
19. Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination.
Kumar S; Wong H; Yeung SA; Riggs KW; Abbott FS; Rurak DW
Drug Metab Dispos; 2000 Jul; 28(7):857-64. PubMed ID: 10859160
[TBL] [Abstract][Full Text] [Related]
20. Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-Delta 2-valproic acid in rabbits.
Scism JL; Powers KM; Artru AA; Chambers AC; Lewis L; Adkison KK; Kalhorn TF; Shen DD
Drug Metab Dispos; 1997 Dec; 25(12):1337-46. PubMed ID: 9394022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
